THINK Surgical Receives FDA Clearance of 2nd Generation Active Robot: Features Unique Upgrades to the Current System

November 20, 2020

THINK Surgical reports the FDA has cleared the second-generation of the TSolution One Total Knee Application.

THINK Surgical describes the system features as an active robot for total knee replacement, providing fully automated bone preparation, and gives surgeons a choice of implant options. The new system features upgrades to the current system, including an enhanced pre-surgical planning user interface, quick-change tooling, improved surgeon accessories, and advanced bone model generation. The clearance of the second-generation TSolution One Total Knee Application comes approximately one year after THINK’s first-generation active robot was cleared.

“The ongoing evolution of the TSolution One Total Knee Application is a testament to THINK Surgical’s dedication and investment in advancing the use of robot technology in the orthopedic setting,” said Jay Yang, acting CEO, THINK Surgical. “The versatile, open platform provides surgeons with the flexibility of using a variety of implants, while offering hospitals and ambulatory surgery centers a sustainable, high throughput system for their ever-increasing total knee replacement procedures.”

The TSolution One total Knee Application is comprised of TPLAN®, the 3D pre-surgical planning workstation, and TCAT®, the active robot that helps the surgeon execute each patient’s individual preoperative plan with consistent results through fully automated bone preparation. This second-generation robot incorporates several changes to the hardware and software, which significantly enhance the system’s efficiency, flexibility and ease of use while maintaining the precision and innovation that is the hallmark of the TSolution One Total Knee Application system.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.
Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic. Phase 1A clinical trial to initiate patient enrolment in 2024. Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

By using this website you agree to accept Medical Device News Magazine Privacy Policy